October 2, 2006

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Revisions to Guidelines for the Management of Anaphylaxis

Please note the following revisions to the Communicable Disease Control Manual, Chapter 2: Immunization Section V: Anaphylaxis:

(1) New Subsections:
   • 1.2 Definitions
   • 1.3 Presentation
   • 1.4 Assessment
   • 1.5 Action of Epinephrine:
     • Background information to the revised guidelines: Intramuscular epinephrine injections into the thigh (vastus lateralis) have been reported to provide more rapid absorption and higher plasma epinephrine levels in both children and adults than intramuscular or subcutaneous injections administered into the arm.
     • Subcutaneous administration of epinephrine is no longer recommended - higher and more rapid concentrations of epinephrine are achieved after IM administration.

(2) Page 4, Section 3.0 Supervision of Vaccinee Post-Immunization:
   • TB skin test recipients should also be advised to remain under supervision for at least 15 minutes after product administration.

Administrative Circular # 2006:12
(3) Page 6, Section 5.0 Administration of Epinephrine:
• Recommendation is to give epinephrine intramuscularly (IM) preferentially into an anterolateral thigh site (vastus lateralis) – to all ages. If administration into a thigh site is problematic, epinephrine may be administered IM into the deltoid muscle of children ≥ 12 months of age and to adults.
• Repeat epinephrine at 5-minute intervals as needed to a maximum of 3 doses (previously had recommended at 10 to 15 minute intervals).

(4) Page 8, Section 10.0 Maintenance of Epinephrine Vials and Other Emergency Supplies:
• Suggested content for epinephrine kits

(5) Page 10, Worksheet for Emergency Treatment of Anaphylaxis:
• Reorganized the flow of the worksheet to reflect the sequencing of tasks (i.e. assessing pulse and respirations before administering dose(s) of epinephrine and diphenhydramine hydrochloride.

Please remove and destroy the following pages from the Communicable Disease Control Manual, Chapter 2 – Immunization Program, Section V Anaphylaxis:
Table of Contents Dated June 2005
Pages 1, 2, 3 & 9 Dated June 2003
Pages 4, 7, 8 Dated August 2004
Pages 5 and 6 Dated June 2005

Insert the following replacement pages into the Communicable Disease Control Manual, Chapter 2 – Immunization Program, Section V Anaphylaxis:
Table of Contents
Pages 1 – 11 Dated October 2006

If you have any questions or concerns, please contact Karen Pielak, Nurse Epidemiologist, at telephone (604)660-6061, fax (604)660-0197 or by email at karen.pielak@bccdc.ca

Sincerely,

David Patrick
Director
Epidemiology Services
BC Centre for Disease Control
pc: Dr Perry Kendall
Provincial Health Officer
Ministry of Health Services

Dr. Bob Fisk
Medical Consultant
Non-Communicable Disease
Ministry of Health Planning

Craig Thompson
Manager, Communicable Disease Prevention --Immunization
Communicable Disease and Addiction Prevention
Ministry of Health Services

Dr. Eric Young
Deputy Provincial Health Officer
Ministry of Health Services

Warren O’Briain
Executive Director
Comm Disease and Addiction Prevention
Ministry of Health Services

Epidemiology Services
655 West 12th Avenue
Vancouver, British Columbia
Canada V5Z 4R4
Tel 604.660.6061
Direct 604.660.5693
Fax 604.660.0197
www.bccdc.org